Comparing Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX)

Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Earnings & Valuation

This table compares Biora Therapeutics and Moleculin Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biora Therapeutics	$892,000.00	0.90	-$124.11 million	($13.04)	-0.01
Moleculin Biotech	N/A	N/A	-$29.77 million	N/A	N/A

Moleculin Biotech has lower revenue, but higher earnings than Biora Therapeutics.

Insider & Institutional Ownership

43.7% of Biora Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 51.1% of Biora Therapeutics shares are held by company insiders. Comparatively, 7.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Biora Therapeutics and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biora Therapeutics	N/A	N/A	-332.47%
Moleculin Biotech	N/A	-157.44%	-97.16%

Analyst Recommendations

This is a breakdown of recent ratings for Biora Therapeutics and Moleculin Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biora Therapeutics	0	0	1	0	3.00
Moleculin Biotech	0	0	2	0	3.00

Biora Therapeutics presently has a consensus target price of $23.00, indicating a potential upside of 12,814.09%. Moleculin Biotech has a consensus target price of $24.00, indicating a potential upside of 1,311.76%. Given Biora Therapeutics’ higher possible upside, research analysts plainly believe Biora Therapeutics is more favorable than Moleculin Biotech.

Volatility and Risk

Biora Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.

Summary

Biora Therapeutics beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.